Lentivector-based polymeric nanoparticles for in situ gene delivery
Alaya.bio has developed innovative nanoparticles utilizing biodegradable polymers and lentivectors for targeted genetic material delivery into cells, enhancing stability and reducing toxicity. This GMP-compatible technology shows promise for therapeutic applications in cancer and gene therapy.
Overview
Alaya.bio presents a cutting-edge solution combining lentivectors (LVs) with biodegradable polymers to create nanoparticles capable of delivering genetic material directly into specific cells. This technology utilizes pH-responsive cationic polymers to activate LVs for cell transduction, while shielding polymers enhance stability and reduce immune responses. This approach is particularly beneficial for in vivo applications, offering a robust manufacturing process that aligns with GMP standards.
Technical specifications
- Lentivectors (LVs): VSV-G-deficient, requiring polymer coating for transduction.
- Polymers: Includes cationic and shielding polymers, formulated from 40 screened families with varied structures and properties.
- Manufacturing: Utilizes microfluidic processes for consistent nanoparticle production.
- Applications: Efficient gene delivery demonstrated in vitro; potential for long-term RNA expression with non-integrative LVs.
Technology readiness level
This technology is at TRL 4, indicating that the solution has been validated in laboratory settings. Future validation includes targeting nanoparticles and in vivo proofs of concept in humanized mouse models to test anticancer efficacy and biodistribution, paving the way for further development and application.
About Alaya.bio
Alaya.bio is a biotech developing a targeting polymeric nanoparticle platform for CAR‑T cell immunotherapies, with an emphasis on in situ (in vivo) approaches. The company’s platform is described as using targeting agents grafted onto a polymeric nanoparticle shell to direct nanoparticles to T cells, with the goal of efficient and safe delivery of therapeutic payloads. Alaya.bio states that its nanoparticle enhances transduction efficiency of quiescent cells such as T cells and NK cells while preserving naive and memory phenotypes, and that it can be used either ex vivo (as part of rapid manufacturing processes) or in vivo (in situ transduction after systemic administration). [1][4][6]
Alaya.bio positions its approach as a way to address hurdles of traditional ex vivo CAR‑T therapies, including complexity, long manufacturing cycles, and high cost. Its collaboration announcement describes advancing research into in situ CAR‑T cell therapies with a focus on evaluating faster, more effective, and cost‑efficient treatments; it also describes a plan to advance the polymeric delivery platform toward clinical translation in hematological malignancies. Separately, Alaya.bio’s acquisition of key assets from Ixaka France is described as providing preclinical proof-of-concept data for in vivo engineered CAR‑T cells and intellectual property supporting its in vivo gene delivery platform. [4][6]
delivered to your inbox.